Tumor infiltrating lymphocyte

Tumor infiltrating lymphocytes are white blood cells that have left the bloodstream and migrated into a tumor.

They are an important prognostic factor in melanoma,[1] [2] higher levels being associated with a better outcome.

They are key to an experimental autologous cell therapy (Contego) for metastatic melanoma.[3]

See also Lymphocyte#Tumor-Infiltrating Lymphocytes

References

  1. ^ Spatz et al. (2007). "Protective effect of a brisk tumor infiltrating lymphocyte infiltrate in melanoma: An EORTC melanoma group study.". Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 8519. http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=34439. 
  2. ^ Galon et al. (2006). "Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome.". Science 29 September 2006: 313 (5795), 1960-1964. http://www.sciencemag.org/content/313/5795/1960.short. 
  3. ^ "Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma". June 2011. http://www.news-medical.net/news/20110606/Genesis-Biopharma-expands-clinical-focus-to-develop-Contego-for-Stage-IV-metastatic-melanoma.aspx. 

External links

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".